CARSON TAHOE CONTINUING CARE HOSPITA
1. Target Overview & Investment Thesis
CARSON TAHOE CONTINUING CARE HOSPITA is a 29-bed under-performing / distressed in CARSON CITY, NV with $5.1M in net patient revenue and a -81.0% operating margin. The hospital serves a payer mix of 39.6% Medicare, 26.3% Medicaid, and 34.2% commercial.
Thesis: Turnaround. Our ML models identify $389K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -81.0% to -73.5% (+759bps).
| Net Revenue HCRIS | $5.1M |
| Current EBITDA COMPUTED | $-4.2M |
| Operating Margin COMPUTED | -81.0% |
| Occupancy HCRIS | 40.9% |
| Revenue / Bed COMPUTED | $177K |
| Net-to-Gross HCRIS | 19.5% |
| Distress Probability ML | 56.4% |
2. Market Context & Competitive Position
NV has 58 Medicare-certified hospitals with a median operating margin of 0.4%. The target's margin of -81.0% places it below the state median. Among 14 size-comparable peers (14-58 beds), the median margin is 4.7%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (14-58), prioritizing same-state peers. 14 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| CARSON TAHOE CONTINUING CARE H (Target) | NV | 29 | $5.1M | -81.0% |
| CARSON VALLEY MEDICAL CENTER | NV | 23 | $84.3M | 6.8% |
| BANNER CHURCHILL COMMUNITY HOS | NV | 25 | $69.2M | 6.8% |
| DIGINTY HEALTH ST ROSE DOMINIC | NV | 32 | $61.5M | 12.2% |
| HUMBOLDT GENERAL HOSPITAL | NV | 25 | $58.8M | -37.3% |
| PAM REHAB HOSP OF CENTENNIAL H | NV | 44 | $35.7M | 29.1% |
| WILLIAM BEE RIRIE HOSPITAL | NV | 25 | $35.1M | -17.9% |
| MESA VIEW REGIONAL HOSPITAL | NV | 25 | $34.9M | -4.2% |
| DESERT VIEW REGIONAL MEDICAL C | NV | 25 | $34.4M | 2.0% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $389K (759bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $108K | +210bp | 18mo |
| Denial Rate Reduction | 12.0% | 6.5% | $107K | +209bp | 12mo |
| Cost to Collect | 4.5% | 2.5% | $103K | +200bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $62K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $10K | +19bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-4.2M |
| + RCM Uplift | +$389K |
| Pro Forma EBITDA | $-3.8M |
| Current Margin | -81.0% |
| Pro Forma Margin | -73.5% |
| WC Released (1x) | $197K |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-6.4M | $-23.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-6.4M | $-28.0M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-5.8M | $-28.8M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-5.8M | $-33.1M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-7.0M | $-23.4M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-7.0M | $-28.0M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (26.3%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| High | Elevated distress probability | Model estimates 56.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
| Low | Low net-to-gross ratio | Large contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 14 hospitals with 14-58 beds
- Same-state prioritization (n=15)
- Comp margins: P25=-11.4% / P50=4.7% / P75=10.5%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.